Typical India planning band
Private lung cancer treatment may plan around USD 5,000-45,000+, depending on stage and drugs.
India vs Singapore lung cancer planning
Lung cancer treatment cost in India vs Singapore
Lung cancer planning should start with histology, stage, PET-CT or brain MRI findings, pulmonary function, oxygen need, biopsy adequacy, EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS and PD-L1 testing, then the care team can compare surgery, SBRT, chemoradiation, immunotherapy, targeted therapy, pleural care, and follow-up scans. India is usually more affordable for self-pay patients, while Singapore can fit selected patients who prioritize premium thoracic oncology review and can budget for higher private drug and scan costs.
Short answer for lung cancer patients
India is usually lower for lung cancer treatment when biopsy review, molecular testing, imaging, surgery or radiation, systemic therapy, admissions, lodging, caregiver, and surveillance are counted. Singapore can be appropriate for a premium opinion or treatment pathway, but only when both quotes use the same histology, stage, mutation profile, PD-L1 status, oxygen risk, treatment sequence, and drug names.
Use INR, SGD, and USD as planning references. Refresh INR through FBIL and SGD through MAS before deposits because molecular panels, immunotherapy, targeted drugs, radiation technique, admission needs, and exchange settlement can change the payable amount.
Let Us Help You
Share the basics and the Virello team will guide you toward the next step.
Prefer email? Write to support@virellohealth.com.
Reviewed 2026-08-25
Clinical review: Virello Health thoracic oncology review team · Editorial review: Virello Health medical travel editorial team
Reviewed for thoracic oncology consent, oxygen and flight-safety cautions, cross-border targeted therapy continuity, India medical visa, Singapore STVP extension, and HCSA licensing.
Typical Singapore planning band
Singapore private lung cancer care may plan around USD 30,000-2,00,000+ with advanced medicines.
Mutation testing matters
EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, BRAF and PD-L1 can redirect treatment and cost.
Travel safety filter
Low oxygen, pleural effusion, clots, infection, or severe breathlessness may make flying unsafe.
Side-by-side view
Compare India and Singapore for lung cancer treatment
Use this table to check whether two quotes are describing the same patient pathway before comparing the final number.
| Factor | India | Singapore | Patient note |
|---|---|---|---|
| Best cost fit | Often stronger for self-pay staging, systemic therapy, radiation, and longer follow-up. | Fits patients who can afford premium thoracic oncology and drug pricing. | Match stage and markers. |
| Diagnostics | PET-CT, brain MRI, biopsy review, IHC, and molecular testing can be planned affordably. | Singapore testing is structured but private prices can rise quickly. | Confirm tissue adequacy. |
| Surgery | Lobectomy or segmentectomy with ICU backup is usually lower cost. | Singapore thoracic surgery is premium priced. | Check lung function. |
| Radiation | SBRT or chemoradiation plus lodging may be easier to budget. | Singapore radiation can fit high-budget patients. | Count fractions. |
| Drug therapy | Targeted therapy, immunotherapy, and chemo options can be compared by brand. | Singapore private drug bills may dominate total cost. | Exact names. |
| Breathing risk | Travel should wait if oxygen or pleural symptoms are unstable. | Same rule applies for Singapore. | Clearance first. |
| Continuity | Home oncology and pulmonology handover should be arranged. | Singapore records must support local continuation. | No drug gaps. |
Read the estimate
What the numbers assume
Separate histology
Non-small cell, small cell, carcinoid, and metastatic disease need different treatment plans.
Stage precisely
Early, locally advanced, metastatic, oligometastatic, and recurrent disease cannot share one price.
Check molecular completeness
Treatment can change if EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, BRAF, or PD-L1 is missing.
Count systemic therapy
Chemo, immunotherapy, targeted drugs, maintenance, and supportive injections should be named and counted.
Include breathing support
Pleural drainage, oxygen, pulmonary rehab, clot treatment, and infection care can affect cost and travel timing.
Clinical scope
Make sure the same treatment is being compared
Early-stage lung cancer
Surgery or SBRT may be considered depending on lung function, anatomy, and operative risk.
Locally advanced disease
Chemoradiation and immunotherapy sequencing can create a longer, higher-cost pathway.
Metastatic lung cancer
Targeted therapy, immunotherapy, chemo, brain radiation, and symptom control may be combined.
Small cell lung cancer
Chemo, immunotherapy, thoracic radiation, and brain-directed prevention or monitoring may be discussed.
Respiratory support
Oxygen need, pleural effusion, pneumonia, COPD, and clots must be stabilized before travel.
When India may fit
India fit considerations
Full diagnostic value
India often fits patients needing biopsy review, PET-CT, molecular testing, and a second treatment plan.
Long systemic therapy affordability
Lower drug-administration and lodging costs help when cycles or maintenance are expected.
Thoracic surgery options
Indian metro centers can compare open, VATS, robotic, segmentectomy, lobectomy, and pneumonectomy pathways.
Caregiver budget
Lower daily living cost supports longer radiation or chemoradiation stays.
When Singapore may fit
Singapore fit considerations
Premium thoracic review
Singapore may fit patients seeking high-cost private review for biomarkers, surgery, or advanced therapy.
Regional access
Southeast Asian patients may find Singapore logistically easier than longer travel.
Complex molecular opinion
A Singapore opinion can help validate targeted therapy or trial-style discussions.
High private budget
Singapore is more feasible when repeated scans, drugs, specialist fees, and lodging are affordable.
Cost comparison
Hospital, extended-care, and full-trip estimates
| Hospital package | India local | India USD | SGD | Comparator USD | Scope |
|---|---|---|---|---|---|
| Diagnosis and staging | INR 1,00,000-5,00,000 | USD 1,200-6,000 | SGD 6,000-30,000 | USD 4,615-23,080 | Biopsy review, PET-CT, brain MRI, IHC, molecular panel, labs, and tumor board. |
| Surgery or radiation block | INR 4,00,000-20,00,000 | USD 4,800-24,000 | SGD 35,000-1,40,000 | USD 26,925-1,07,690 | Lobectomy, segmentectomy, SBRT, chemoradiation, ICU, anesthesia, planning, and early follow-up. |
| Advanced systemic therapy | INR 10,00,000-60,00,000+ | USD 12,000-72,000+ | SGD 1,00,000-4,00,000+ | USD 76,920-3,07,690+ | Immunotherapy, targeted therapy, maintenance, brain treatment, repeated scans, and complications. |
| Extended care | India local | India USD | SGD | Comparator USD | Scope |
|---|---|---|---|---|---|
| Molecular and PD-L1 testing | INR 60,000-4,00,000 | USD 720-4,800 | SGD 4,000-25,000 | USD 3,080-19,230 | NGS, EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, BRAF, PD-L1, and repeat biopsy if tissue is inadequate. |
| Pleural or oxygen support | INR 40,000-3,00,000 | USD 480-3,600 | SGD 3,000-22,000 | USD 2,310-16,925 | Pleural tap, drain, pleurodesis, oxygen assessment, infection care, or pulmonary consultation. |
| Radiation planning add-ons | INR 2,00,000-8,00,000 | USD 2,400-9,600 | SGD 15,000-70,000 | USD 11,540-53,850 | SBRT, IMRT, VMAT, brain SRS, simulation, motion management, and image guidance. |
| Monitoring quarter | INR 60,000-3,50,000 | USD 720-4,200 | SGD 5,000-28,000 | USD 3,845-21,540 | CT or PET-CT, brain imaging, labs, side-effect review, pulmonary care, and medicine changes. |
| Complete trip budget | India local | India USD | SGD | Comparator USD | Scope |
|---|---|---|---|---|---|
| Flights with breathing assessment | Origin dependent | USD 300-2,200+ | Origin dependent | USD 180-1,800+ | Oxygen, clot risk, pleural fluid, and fitness-to-fly review may be needed. |
| Visa or visit-pass extension | Nationality dependent | Varies | SGD 40+ if extension applies | USD 30+ | Long chemoradiation or complication care may need extended stay planning. |
| Treatment lodging | INR 3,000-14,000/night | USD 35-170/night | SGD 150-650/night | USD 115-500/night | Daily radiation, chemo, pulmonary care, and scan visits need nearby stay. |
| Caregiver support | INR 2,000-9,000/day | USD 25-110/day | SGD 80-320/day | USD 60-245/day | Breathing support, medicines, food, symptom monitoring, and transport. |
| Local transport | INR 1,000-5,500/visit | USD 12-65/visit | SGD 45-260/visit | USD 35-200/visit | Radiation, chemo daycare, scan, blood test, and pulmonology visits. |
| Nutrition and symptom supplies | INR 1,500-7,000/day | USD 18-85/day | SGD 80-280/day | USD 60-215/day | Protein support, masks, inhalers if prescribed, dressings, thermometer, and hydration. |
| Delay reserve | 20-35% of care budget | Reserve in USD | 25-45% of care budget | Reserve in USD | Low oxygen, fever, clot, pleural fluid, drug toxicity, or brain symptoms can delay travel. |
| Home oncology and pulmonology | Home pricing | Varies | Home pricing | Varies | Drug continuation, scans, oxygen review, pulmonary rehab, and emergency plan. |
Usually included
What should be inside the quote
Histology and stage
NSCLC or SCLC subtype, stage, spread sites, and performance status should be written.
Care anchor.
Molecular profile
EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, BRAF, PD-L1 and test method should be listed.
Drug decision.
Imaging plan
PET-CT, brain MRI, CT chest, bone imaging, and response scans should be clarified.
Stage proof.
Surgery scope
Segmentectomy, lobectomy, pneumonectomy, nodes, approach, ICU, and lung function criteria should be stated.
If operable.
Radiation details
SBRT, IMRT, VMAT, brain SRS, fractions, and planning method should be included.
If needed.
Drug plan
Chemo, immunotherapy, targeted therapy, maintenance, dose, cycle count, and supportive drugs should be named.
Cost driver.
Breathing support
Oxygen, pleural care, pulmonary rehab, inhaler plan, and clot prevention should be discussed.
Travel safety.
Records for home
Pathology, mutation report, scan files, treatment summary, toxicity notes, and prescriptions should come home.
Continuity.
Confirm separately
What may sit outside the quote
Incomplete tissue
Repeat biopsy or liquid biopsy may be needed if molecular testing is insufficient.
Can add cost.
Brain metastasis care
Brain MRI, SRS, surgery, steroids, or admission may not be included in baseline quotes.
Ask early.
Pleural procedures
Pleural drainage, catheter, pleurodesis, or oxygen equipment may be separate.
Breathing cost.
Targeted drugs
Mutation-driven medicines can dominate budget and may continue long term.
Name drug.
Immunotherapy toxicity
Lung, bowel, liver, endocrine, or skin side effects may require admission or steroids.
Reserve.
Singapore subsidy boundary
Resident subsidy or public context should not be treated as foreign private self-pay cost.
Private quote.
Smoking or COPD optimization
Pulmonary rehab, inhaler adjustment, or infection care may be outside treatment package.
Optimize.
Home continuation
Later cycles, targeted refills, scans, oxygen, and emergency care at home are separate.
Plan ahead.
Cost drivers
Why two estimates may differ
Histology
Small cell and non-small cell lung cancers follow different protocols.
Subtype first.
Mutation result
Actionable mutations can shift care toward long-term targeted therapy.
Test complete.
PD-L1 and immunotherapy
Immunotherapy eligibility and duration can sharply raise cost.
Biomarker driven.
Stage and spread
Brain, bone, liver, adrenal, or pleural spread changes scans and treatment.
Image fully.
Lung function
Poor pulmonary function can limit surgery and increase hospital risk.
PFT needed.
Radiation precision
SBRT, SRS, motion management, and image guidance have different budgets.
Technique matters.
Singapore private billing
Specialist, scan, drug, facility, GST, ward, and emergency fees need itemization.
Detailed quote.
Travel delay
Oxygen need, clots, infection, or pleural fluid can postpone flying.
Clearance required.
Hospital selection
Choose capability before package price
Licensed thoracic oncology
Singapore care should be through appropriately licensed healthcare services.
HCSA check.
Biopsy capability
Bronchoscopy, CT-guided biopsy, EBUS, pathology, and molecular testing should be coordinated.
Tissue matters.
Multidisciplinary review
Thoracic surgeon, medical oncologist, radiation oncologist, pulmonologist, radiologist, and pathologist should align.
Team decision.
Thoracic surgery depth
Confirm VATS, robotic, open surgery, ICU, and air-leak management experience.
If operable.
Radiation precision
SBRT, IMRT, VMAT, SRS, and motion management should match the disease site.
Technology fit.
Drug access
Ask how targeted drugs, immunotherapy, biosimilars, and supportive medicines are sourced.
Cost clarity.
Respiratory emergency support
Pleural effusion, oxygen drop, infection, and clot symptoms need rapid care pathways.
Safety.
Treating team
Specialists to verify
Thoracic oncologist
Choose a team that routinely treats lung cancer by subtype, stage, and mutation profile.
Pulmonologist
Breathing symptoms, biopsy adequacy, oxygen risk, and COPD optimization need pulmonary input.
Thoracic surgeon
Operable patients should discuss lung function, lymph nodes, approach, ICU, and recovery.
Radiation oncologist
SBRT, chemoradiation, or brain radiation should be explained with side-effect and fraction details.
Home care link
Home oncology and pulmonology should be ready for drugs, scans, oxygen, and emergency symptoms.
Patient journey
From report review to return-home continuity
Share pathology and scans
Upload biopsy, IHC, PET-CT, CT, brain MRI, labs, symptoms, and prior treatment.
Confirm tissue and markers
Ask whether repeat biopsy, liquid biopsy, or broader NGS is needed.
Define stage and intent
Clarify curative surgery, SBRT, chemoradiation, systemic control, or palliative focus.
Compare same-plan quotes
Match surgery, radiation, drug names, cycles, scans, oxygen support, and admissions.
Check travel fitness
Assess oxygen level, pleural fluid, clot risk, infection, pain, and performance status.
Monitor during treatment
Track breathing, fever, cough, blood counts, liver tests, skin, diarrhea, and fatigue.
Continue locally
Arrange medication supply, scans, oncology visits, pulmonary care, and emergency access at home.
Travel and stay planning
Before booking
Confirm histology, stage, mutation testing status, and oxygen stability.
Core safety.
Before flight
Check pulse oximetry, clot risk, pleural effusion, infection, and pain control.
Clearance.
Arrival
Complete biopsy review, PET-CT, brain MRI, molecular testing, and tumor board if needed.
Plan may change.
During therapy
Track fever, breathlessness, cough, diarrhea, rash, weakness, and blood counts.
Report early.
Radiation period
Daily visits require lodging close to hospital and transport that avoids fatigue.
Plan route.
Return timing
Fly after oxygen, fever, hydration, pain, clot risk, and medicine plan are stable.
Written note.
After return
Home oncologist should receive mutation report, scans, drug plan, and toxicity summary.
No interruption.
Legal and eligibility checks
India medical visa
Use the official India e-Visa portal for medical visa and attendant planning.
Singapore visit duration
Check short-term visit pass duration before committing to radiation or multi-cycle therapy.
Medical extension support
ICA may require doctor-endorsed Form V75 when treatment delays require an extension.
Consent topics
Consent should cover biopsy, surgery, radiation, systemic therapy, fertility, oxygen risk, and emergency admission.
Safety and risks
What can change the plan
Low oxygen
Low saturation or oxygen need can make flying unsafe.
Assess first.
Pleural effusion
Fluid around the lung may need drainage before travel.
Breathing risk.
Blood clots
Cancer and long flights can increase clot risk.
Ask prevention.
Fever or infection
Pneumonia or chemo-related fever needs urgent care.
Do not delay.
Immunotherapy toxicity
Inflammation in lung, bowel, liver, glands, or skin can be serious.
Know symptoms.
Brain symptoms
Headache, weakness, seizures, or confusion need urgent review.
MRI may be needed.
Cost escalation
New mutation tests, brain treatment, oxygen care, or admissions can raise totals.
Reserve.
Recovery and continuity
Plan after discharge
Mutation report
Carry molecular panel, PD-L1, pathology, and specimen details.
Treatment summary
Keep drug names, doses, cycles, radiation fields, surgery details, and toxicities.
Scan calendar
Know timing for CT, PET-CT, brain MRI, and response review.
Breathing plan
Arrange oxygen review, inhalers, pulmonary rehab, and pleural care if needed.
Drug supply
Plan targeted therapy or immunotherapy access at home before leaving.
Side-effect monitoring
Track diarrhea, rash, cough, fever, fatigue, jaundice, and appetite changes.
Emergency access
Know where to go for breathlessness, fever, chest pain, coughing blood, confusion, or severe weakness.
Decision guide
Match the country to the patient scenario
Mutation-positive metastatic cancer
India may fit when long-term targeted therapy cost must stay manageable.
Premium molecular review
Singapore may fit if private testing and specialist opinion are affordable.
Breathless patient
Oxygen or pleural instability should be stabilized before any destination decision.
| Factor | India may fit when | Singapore may fit when | Verify before booking |
|---|---|---|---|
| Molecular testing | Broad testing can be budgeted more affordably. | Premium molecular review is preferred. | NGS and PD-L1. |
| Drug duration | Lower long-term therapy cost matters. | High private drug cost is acceptable. | Drug names. |
| Surgery eligibility | Thoracic surgery and ICU cost are lower. | Premium thoracic unit fits budget. | PFT and stage. |
| Radiation stay | Daily treatment lodging is manageable. | Singapore stay cost is acceptable. | Fractions. |
| Travel safety | Oxygen and clot risk are stable for flight. | Regional travel is safer or shorter. | Fitness note. |
| Documents | Medical visa supports treatment stay. | STVP extension path is ready. | Entry plan. |
Reports and questions
Prepare before asking hospitals to quote
Reports to share
Biopsy and histology
Share pathology, IHC, specimen site, and tissue adequacy notes.
Molecular results
Include EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, BRAF, PD-L1, and NGS reports.
Imaging files
Upload PET-CT, CT chest, brain MRI, bone scan, and prior comparison images.
Pulmonary tests
Include oxygen saturation, PFT, COPD history, inhalers, and pleural procedure records.
Treatment history
List surgery, radiation, chemo, immunotherapy, targeted drugs, and side effects.
Symptoms
Mention cough, blood in sputum, breathlessness, pain, weight loss, fever, or brain symptoms.
Labs and medicines
Share blood counts, kidney, liver, electrolytes, current drugs, blood thinners, and allergies.
Travel constraints
State origin, caregiver, oxygen needs, budget, visa status, urgency, and return deadline.
Quote questions
What subtype is priced?
Ask whether the plan is for NSCLC, SCLC, or another lung tumor.
Is molecular testing complete?
Confirm mutation panel, PD-L1, tissue adequacy, and repeat biopsy policy.
What is the treatment intent?
Clarify surgery, SBRT, chemoradiation, systemic control, or symptom relief.
Which drugs are included?
Request generic name, brand, dose, cycle count, and maintenance duration.
What radiation is planned?
Ask technique, site, fractions, motion management, and side-effect care.
What breathing care is excluded?
Clarify oxygen, pleural drainage, infection admission, and pulmonary rehab.
What if stay extends?
Ask about ICA extension support, hospital letters, and extra lodging cost.
What records come home?
Request mutation report, scan files, treatment summary, toxicity notes, prescriptions, and flight note.
Questions for clinicians
Is tissue enough for testing?
Ask whether biopsy material supports all required markers.
What stage am I?
Clarify PET-CT, brain MRI, nodes, and spread sites.
Am I operable?
Discuss lung function, tumor location, lymph nodes, and surgical risk.
Which drug comes first?
Ask how mutation and PD-L1 results affect targeted therapy, immunotherapy, or chemo.
Can I fly safely?
Review oxygen, pleural fluid, clot risk, infection, pain, and performance status.
How do I continue care?
Plan home drug supply, scans, emergency care, and pulmonary follow-up.
Related guidance
Continue comparing with the right context
Compare treatment costs Browse country comparison guides. India vs Singapore overview Compare destination planning. Lung cancer cost in India Review India lung cancer pricing. Lung cancer cost by country Check Singapore planning assumptions. Lung cancer treatment in India Understand lung cancer pathways. Cancer hospitals in India Compare oncology hospitals. Lung cancer specialists in India Review doctor selection. Medical tourism in India Plan treatment travel. Medical report review Prepare pathology and scan files. Second opinion Review lung cancer plan. Treatment quote Request itemized estimates. Medical visa assistance Prepare patient and attendant documents.
Common questions
Questions patients ask before comparing countries
Is lung cancer treatment cheaper in India than Singapore?
India is usually lower for self-pay patients after staging, molecular tests, surgery or radiation, drugs, lodging, caregiver, and follow-up are included.
What changes lung cancer cost most?
Stage, histology, mutation status, PD-L1, targeted therapy, immunotherapy, radiation type, surgery eligibility, oxygen care, and complications.
Why are molecular tests important?
Mutation and PD-L1 results can decide whether targeted therapy, immunotherapy, chemotherapy, or radiation should be used.
Can I travel with breathlessness?
Only after medical clearance. Low oxygen, pleural effusion, infection, or clot risk can make flying unsafe.
Can Singapore public cost references be used?
Foreign self-pay patients should use hospital-specific private quotes, not resident subsidy assumptions.
What records are needed for a lung cancer quote?
Biopsy, IHC, molecular report, PET-CT, brain MRI, CT images, labs, symptoms, medicines, and prior treatment.
Is surgery always possible?
No. Stage, tumor location, lymph nodes, lung function, heart health, and overall fitness decide operability.
What if treatment continues for months?
Some patients start abroad and continue drugs, scans, or cycles at home if records and medicine access are coordinated.
What if Singapore stay extends?
ICA may require doctor-endorsed medical documents for treatment-related stay extension.
Can Virello compare lung cancer plans?
Virello can organize reports, check missing biomarkers, compare itemized estimates, and coordinate second opinions.
Method and sources
How this comparison is reviewed
This lung cancer comparison separates histology, stage, biopsy adequacy, molecular testing, PD-L1, lung function, surgery, SBRT or chemoradiation, systemic therapy, oxygen and pleural risk, Singapore private-fee context, STVP extension, India medical visa, MAS and FBIL currency references, and home oncology handover. Email support@virellohealth.com for report-led coordination.
ICA extension of visit pass Singapore medical-treatment extension guidance. Singapore HCSA licensing Healthcare services regulation and licensing context. Singapore foreign patient context Foreign-patient public hospital context. India e-Visa portal India medical visa source. NCI non-small cell lung cancer treatment NSCLC treatment patient education. American Cancer Society lung cancer treatment Lung cancer treatment context. Financial Benchmarks India INR reference source. MAS exchange rates SGD reference source. Virello lung cancer cost in India Internal lung cancer cost guide. Virello medical report review Internal lung cancer report workflow.
Need a report-led comparison?
Share reports before choosing a country
Virello Health can help organize the case summary, quote questions, hospital scope, and practical next steps. For written communication, use support@virellohealth.com.